← Leaderboards
Zhaohui Feng
Univ Of Med/Dent Nj-R W Johnson Med Sch
$7,437,486
Attributed
$9,456,270
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,456,270 · 5
By mechanism
R01$9,456,270 · 5
Top collaborators
- Wenwei Hu10 shared
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelTp53 GenePlayTumorigenesisTumorBaseRegulationCancer TherapyMalignant NeoplasmsMutationCancer CellSamplingTargeted TreatmentEnzymesNew Therapeutic TargetGenesMutantColorectal Cancer TreatmentColorectal NeoplasmsMolecularColorectal CancerColon TumorigenesisMediatingTumor Suppression
Grant awards (26)
Gain-of-function mutant p53 and metabolic reprogramming in colorectal cancer$459,611
R01 · FY2025 · CA
The regulation of mutant p53 protein accumulation in cancer: molecular basis and therapeutic potential$418,341
R01 · FY2025 · CA · contact PI
Gain-of-function mutant p53 and metabolic reprogramming in colorectal cancer$436,631
R01 · FY2024 · CA
The regulation of mutant p53 protein accumulation in cancer: molecular basis and therapeutic potential$397,425
R01 · FY2024 · CA · contact PI
Gain-of-function mutant p53 and metabolic reprogramming in colorectal cancer$450,420
R01 · FY2023 · CA
The regulation of mutant p53 protein accumulation in cancer: molecular basis and therapeutic potential$409,975
R01 · FY2023 · CA · contact PI
Gain-of-function mutant p53 and metabolic reprogramming in colorectal cancer$450,420
R01 · FY2022 · CA
The regulation of mutant p53 protein accumulation in cancer: molecular basis and therapeutic potential$409,975
R01 · FY2022 · CA · contact PI
SENP6, a novel p53 negative regulator, is an important new player in cancer$356,438
R01 · FY2022 · CA · contact PI
Metabolic reprogramming in breast cancer$356,438
R01 · FY2022 · CA · contact PI
Gain-of-function mutant p53 and metabolic reprogramming in colorectal cancer$440,108
R01 · FY2021 · CA
The regulation of mutant p53 protein accumulation in cancer: molecular basis and therapeutic potential$413,128
R01 · FY2021 · CA · contact PI
SENP6, a novel p53 negative regulator, is an important new player in cancer$363,713
R01 · FY2021 · CA · contact PI
Metabolic reprogramming in breast cancer$363,713
R01 · FY2021 · CA · contact PI
SENP6, a novel p53 negative regulator, is an important new player in cancer$363,713
R01 · FY2020 · CA · contact PI
Metabolic reprogramming in breast cancer$363,713
R01 · FY2020 · CA · contact PI
SENP6, a novel p53 negative regulator, is an important new player in cancer$352,801
R01 · FY2019 · CA · contact PI
Metabolic reprogramming in breast cancer$352,801
R01 · FY2019 · CA · contact PI
Metabolic reprogramming in breast cancer$363,713
R01 · FY2018 · CA · contact PI
SENP6, a novel p53 negative regulator, is an important new player in cancer$363,713
R01 · FY2018 · CA · contact PI
The role of glutaminase 2, a novel p53 target gene in metabolism, in liver cancer$308,825
R01 · FY2014 · CA · contact PI
The role of glutaminase 2, a novel p53 target gene in metabolism, in liver cancer$222,575
R01 · FY2013 · CA · contact PI
The role of glutaminase 2, a novel p53 target gene in metabolism, in liver cancer$75,704
R01 · FY2013 · CA · contact PI
The role of glutaminase 2, a novel p53 target gene in metabolism, in liver cancer$312,891
R01 · FY2012 · CA · contact PI
The role of glutaminase 2, a novel p53 target gene in metabolism, in liver cancer$314,790
R01 · FY2011 · CA · contact PI
The role of glutaminase 2, a novel p53 target gene in metabolism, in liver cancer$334,695
R01 · FY2010 · CA · contact PI